Terms: = Lung cancer AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1 AND Diagnosis
15 results:
1. Multi-gene Liquid Biopsy to Detect Resistance to First-line Osimertinib in Patients With
Ito S; Tsurumi K; Shindo N; Soma S; Yamaguchi K; Tamai K; Mochizuki M; Fujimori H; Morita M; Watanabe K; Suzuki A; Fukuhara T; Yasuda J
Anticancer Res; 2023 Nov; 43(11):5031-5040. PubMed ID: 37909987
[TBL] [Abstract] [Full Text] [Related]
2. Pulmonary Langerhans cell histiocytosis - an update on pathogenesis and treatment.
Jouenne F; Benattia A; Tazi A
Curr Opin Pulm Med; 2023 Sep; 29(5):451-458. PubMed ID: 37410483
[TBL] [Abstract] [Full Text] [Related]
3. Multi-Omics Immune Interaction Networks in lung cancer Tumorigenesis, Proliferation, and Survival.
Ye Q; Hickey J; Summers K; Falatovich B; Gencheva M; Eubank TD; Ivanov AV; Guo NL
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499305
[TBL] [Abstract] [Full Text] [Related]
4. Semi-Supervised Adversarial Learning for Improving the diagnosis of Pulmonary Nodules.
Fu Y; Xue P; Xiao T; Zhang Z; Zhang Y; Dong E
IEEE J Biomed Health Inform; 2023 Jan; 27(1):109-120. PubMed ID: 36269913
[TBL] [Abstract] [Full Text] [Related]
5. Analysis of Circulating Tumor and cancer Stem Cells Provides New Opportunities in diagnosis and Treatment of Small Cell lung cancer.
Skurikhin EG; Ermakova N; Zhukova M; Pershina O; Pan E; Pakhomova A; Kogai L; Goldberg V; Simolina E; Skurikhina V; Widera D; Kubatiev A; Morozov SG; Kushlinskii N; Dygai A
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142766
[TBL] [Abstract] [Full Text] [Related]
6. Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study.
Kemps PG; Zondag TCE; Arnardóttir HB; Solleveld-Westerink N; Borst J; Steenwijk EC; van Egmond D; Swennenhuis JF; Stelloo E; Trambusti I; Verdijk RM; van Noesel CJM; Cleven AHG; Scheijde-Vermeulen MA; Koudijs MJ; Krsková L; Hawkins C; Egeler RM; Brok J; von Bahr Greenwood T; Svojgr K; Beishuizen A; van Laar JAM; Pötschger U; Hutter C; Sieni E; Minkov M; Abla O; van Wezel T; van den Bos C; van Halteren AGS
Blood Adv; 2023 Feb; 7(4):664-679. PubMed ID: 36083130
[TBL] [Abstract] [Full Text] [Related]
7. Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers.
Liu CY; Lin HF; Lai WY; Lin YY; Lin TW; Yang YP; Tsai FT; Wang CL; Luo YH; Chen YM; Hsu PK; Kai LJ; Kiat AOH; Chien Y; Chiou SH; Wang CY
J Chin Med Assoc; 2022 Apr; 85(4):409-413. PubMed ID: 35383703
[TBL] [Abstract] [Full Text] [Related]
8. Clinical and genetic characteristics of early-stage multiple primary and independent primary lung adenocarcinoma patients.
Li P; Yang R; Wang D; Wang L; Wang S; Liu C; Li J; Li L; Liu C; Tong Y; Wang Y
Asia Pac J Clin Oncol; 2022 Oct; 18(5):e420-e426. PubMed ID: 35098658
[TBL] [Abstract] [Full Text] [Related]
9. NGS Analysis of Liquid Biopsy (LB) and Formalin-Fixed Paraffin-Embedded (FFPE) Melanoma Samples Using Oncomine™ Pan-cancer Cell-Free Assay.
Olbryt M; Rajczykowski M; Bal W; Fiszer-Kierzkowska A; Cortez AJ; Mazur M; Suwiński R; Widłak W
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356096
[TBL] [Abstract] [Full Text] [Related]
10. Molecular testing on bronchial washings for the diagnosis and predictive assessment of lung cancer.
Roncarati R; Lupini L; Miotto E; Saccenti E; Mascetti S; Morandi L; Bassi C; Rasio D; Callegari E; Conti V; Rinaldi R; Lanza G; Gafà R; Papi A; Frassoldati A; Sabbioni S; Ravenna F; Casoni GL; Negrini M
Mol Oncol; 2020 Sep; 14(9):2163-2175. PubMed ID: 32441866
[TBL] [Abstract] [Full Text] [Related]
11. Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the lung cancer Mutation Consortium.
Steuer CE; Behera M; Berry L; Kim S; Rossi M; Sica G; Owonikoko TK; Johnson BE; Kris MG; Bunn PA; Khuri FR; Garon EB; Ramalingam SS
Cancer; 2016 Mar; 122(5):766-72. PubMed ID: 26695526
[TBL] [Abstract] [Full Text] [Related]
12. Molecular profiling of small cell lung cancer in a Japanese cohort.
Wakuda K; Kenmotsu H; Serizawa M; Koh Y; Isaka M; Takahashi S; Ono A; Taira T; Naito T; Murakami H; Mori K; Endo M; Nakajima T; Ohde Y; Takahashi T; Yamamoto N
Lung Cancer; 2014 May; 84(2):139-44. PubMed ID: 24657128
[TBL] [Abstract] [Full Text] [Related]
13. Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma.
Rekhtman N; Tafe LJ; Chaft JE; Wang L; Arcila ME; Colanta A; Moreira AL; Zakowski MF; Travis WD; Sima CS; Kris MG; Ladanyi M
Mod Pathol; 2013 Apr; 26(4):511-22. PubMed ID: 23196793
[TBL] [Abstract] [Full Text] [Related]
14. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.
Rekhtman N; Paik PK; Arcila ME; Tafe LJ; Oxnard GR; Moreira AL; Travis WD; Zakowski MF; Kris MG; Ladanyi M
Clin Cancer Res; 2012 Feb; 18(4):1167-76. PubMed ID: 22228640
[TBL] [Abstract] [Full Text] [Related]
15. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Chaft JE; Arcila ME; Paik PK; Lau C; Riely GJ; Pietanza MC; Zakowski MF; Rusch V; Sima CS; Ladanyi M; Kris MG
Mol Cancer Ther; 2012 Feb; 11(2):485-91. PubMed ID: 22135231
[TBL] [Abstract] [Full Text] [Related]
